The amyloid cascade hypothesis: an updated critical review
Results from recent clinical trials of antibodies that target amyloid-β (Aβ) for Alzheimer's
disease have created excitement and have been heralded as corroboration of the amyloid …
disease have created excitement and have been heralded as corroboration of the amyloid …
Alzheimer's disease: From immunotherapy to immunoprevention
M Jucker, LC Walker - Cell, 2023 - cell.com
Recent Aβ-immunotherapy trials have yielded the first clear evidence that removing
aggregated Aβ from the brains of symptomatic patients can slow the progression of …
aggregated Aβ from the brains of symptomatic patients can slow the progression of …
Multiple cerebral hemorrhages in a patient receiving lecanemab and treated with t-PA for stroke
Cerebral Hemorrhages after t-PA in a Patient Treated with Lecanemab A patient with mild
cognitive impairment who was treated in the extension phase of a trial of lecanemab, an …
cognitive impairment who was treated in the extension phase of a trial of lecanemab, an …
Efficacy and safety of anti-amyloid-β monoclonal antibodies in current Alzheimer's disease phase III clinical trials: A systematic review and interactive web app-based …
The risk-benefit profile of anti-Aβ monoclonal antibodies (mAbs) in Alzheimer's disease (AD)
remains unclear, especially concerning their safety and overall effects on AD progression …
remains unclear, especially concerning their safety and overall effects on AD progression …
Key questions for the evaluation of anti-amyloid immunotherapies for Alzheimer's disease
The clinical benefit associated with anti-amyloid immunotherapies, a new class of drugs for
the treatment of Alzheimer's disease, is predicated on their ability to modify disease course …
the treatment of Alzheimer's disease, is predicated on their ability to modify disease course …
Targeting epigenetics: A novel promise for Alzheimer's disease treatment
So far, the search for a cure for Alzheimer Disease (AD) has been unsuccessful. The only
approved drugs attenuate some symptoms, but do not halt the progress of this disease …
approved drugs attenuate some symptoms, but do not halt the progress of this disease …
Alzheimer's disease: insights into pathology, molecular mechanisms, and therapy
Q Zheng, X Wang - Protein & Cell, 2025 - academic.oup.com
Abstract Alzheimer's disease (AD), the leading cause of dementia, is characterized by the
accumulation of amyloid plaques and neurofibrillary tangles in the brain. This condition …
accumulation of amyloid plaques and neurofibrillary tangles in the brain. This condition …
Impacts of FDA approval and Medicare restriction on antiamyloid therapies for Alzheimer's disease: patient outcomes, healthcare costs, and drug development
R Brockmann, J Nixon, BL Love… - The Lancet Regional …, 2023 - thelancet.com
In 2021, the US Food and Drug Administration (FDA) granted approval to aducanumab, an
antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical …
antiamyloid antibody for early-stage Alzheimer's disease, despite a lack of clear clinical …
[HTML][HTML] Anti-Amyloid Therapies for Alzheimer's Disease: An Alzheimer Europe Position Paper and Call to Action
AC Bradshaw, J Georges, AE Board - The journal of prevention of …, 2024 - Elsevier
The growing prevalence and burden of Alzheimer's disease has catalysed huge investments
in research on its causes, diagnosis, treatment and care. After many high-profile failures …
in research on its causes, diagnosis, treatment and care. After many high-profile failures …
Advocating for demonstration of disease modification—have we been approaching clinical trials in early Alzheimer disease incorrectly?
The Alzheimer disease (AD) community was unanimous in welcoming the favorable results
of Clarity AD, 1 an 18-month phase 3 randomized clinical trial of lecanemab in early AD …
of Clarity AD, 1 an 18-month phase 3 randomized clinical trial of lecanemab in early AD …